vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) and GE HealthCare (GEHC), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $487.7M, roughly 11.7× CLOVER HEALTH INVESTMENTS, CORP. /DE). GE HealthCare runs the higher net margin — -10.1% vs 10.3%, a 20.4% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. /DE posted the faster year-over-year revenue change (44.7% vs 7.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP. /DE's revenue compounded faster (18.6% CAGR vs 10.7%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
CLOV vs GEHC — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $487.7M | $5.7B |
| Net Profit | $-49.3M | $588.0M |
| Gross Margin | — | 39.7% |
| Operating Margin | -10.1% | 14.5% |
| Net Margin | -10.1% | 10.3% |
| Revenue YoY | 44.7% | 7.1% |
| Net Profit YoY | -123.2% | -18.4% |
| EPS (diluted) | — | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $487.7M | $5.7B | ||
| Q3 25 | $496.6M | $5.1B | ||
| Q2 25 | $477.6M | $5.0B | ||
| Q1 25 | $462.3M | $4.8B | ||
| Q4 24 | $337.0M | $5.3B | ||
| Q3 24 | $331.0M | $4.9B | ||
| Q2 24 | $356.3M | $4.8B | ||
| Q1 24 | $346.9M | $4.7B |
| Q4 25 | $-49.3M | $588.0M | ||
| Q3 25 | $-24.4M | $446.0M | ||
| Q2 25 | $-10.6M | $486.0M | ||
| Q1 25 | $-1.3M | $564.0M | ||
| Q4 24 | $-22.1M | $721.0M | ||
| Q3 24 | $-9.2M | $470.0M | ||
| Q2 24 | $7.4M | $428.0M | ||
| Q1 24 | $-19.2M | $374.0M |
| Q4 25 | — | 39.7% | ||
| Q3 25 | — | 38.7% | ||
| Q2 25 | — | 39.6% | ||
| Q1 25 | — | 42.1% | ||
| Q4 24 | — | 42.8% | ||
| Q3 24 | 24.5% | 41.7% | ||
| Q2 24 | 30.3% | 41.4% | ||
| Q1 24 | 23.6% | 40.9% |
| Q4 25 | -10.1% | 14.5% | ||
| Q3 25 | -4.9% | 12.7% | ||
| Q2 25 | -2.2% | 13.1% | ||
| Q1 25 | -0.3% | 13.2% | ||
| Q4 24 | -6.4% | 15.1% | ||
| Q3 24 | -2.7% | 13.9% | ||
| Q2 24 | 2.0% | 12.6% | ||
| Q1 24 | -6.5% | 11.6% |
| Q4 25 | -10.1% | 10.3% | ||
| Q3 25 | -4.9% | 8.7% | ||
| Q2 25 | -2.2% | 9.7% | ||
| Q1 25 | -0.3% | 11.8% | ||
| Q4 24 | -6.6% | 13.6% | ||
| Q3 24 | -2.8% | 9.7% | ||
| Q2 24 | 2.1% | 8.8% | ||
| Q1 24 | -5.5% | 8.0% |
| Q4 25 | — | $1.28 | ||
| Q3 25 | — | $0.98 | ||
| Q2 25 | — | $1.06 | ||
| Q1 25 | — | $1.23 | ||
| Q4 24 | — | $1.58 | ||
| Q3 24 | — | $1.02 | ||
| Q2 24 | — | $0.93 | ||
| Q1 24 | — | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.3M | $4.5B |
| Total DebtLower is stronger | — | $10.0B |
| Stockholders' EquityBook value | $308.7M | $10.4B |
| Total Assets | $541.0M | $36.9B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $78.3M | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $3.7B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $194.5M | $2.9B | ||
| Q3 24 | $288.0M | $3.5B | ||
| Q2 24 | $254.8M | $2.0B | ||
| Q1 24 | $208.3M | $2.6B |
| Q4 25 | — | $10.0B | ||
| Q3 25 | — | $10.3B | ||
| Q2 25 | — | $10.3B | ||
| Q1 25 | — | $8.8B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | — | $9.2B | ||
| Q1 24 | — | $9.3B |
| Q4 25 | $308.7M | $10.4B | ||
| Q3 25 | $340.9M | $10.0B | ||
| Q2 25 | $344.2M | $9.7B | ||
| Q1 25 | $336.1M | $9.2B | ||
| Q4 24 | $341.1M | $8.4B | ||
| Q3 24 | $342.2M | $8.3B | ||
| Q2 24 | $324.9M | $7.8B | ||
| Q1 24 | $292.5M | $7.4B |
| Q4 25 | $541.0M | $36.9B | ||
| Q3 25 | $559.7M | $36.1B | ||
| Q2 25 | $575.0M | $35.5B | ||
| Q1 25 | $583.7M | $33.6B | ||
| Q4 24 | $580.7M | $33.1B | ||
| Q3 24 | $653.0M | $33.9B | ||
| Q2 24 | $674.2M | $31.9B | ||
| Q1 24 | $671.8M | $32.2B |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.18× | ||
| Q1 24 | — | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-68.2M | — |
| Free Cash FlowOCF − Capex | $-68.7M | — |
| FCF MarginFCF / Revenue | -14.1% | — |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-69.0M | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $-68.2M | — | ||
| Q3 25 | $12.1M | — | ||
| Q2 25 | $5.4M | $94.0M | ||
| Q1 25 | $-16.3M | $250.0M | ||
| Q4 24 | $-85.8M | — | ||
| Q3 24 | $50.0M | — | ||
| Q2 24 | $44.8M | $-119.0M | ||
| Q1 24 | $25.9M | $419.0M |
| Q4 25 | $-68.7M | — | ||
| Q3 25 | $11.4M | — | ||
| Q2 25 | $4.8M | $8.0M | ||
| Q1 25 | $-16.5M | $98.0M | ||
| Q4 24 | $-86.1M | — | ||
| Q3 24 | $49.6M | — | ||
| Q2 24 | $44.4M | $-183.0M | ||
| Q1 24 | $25.5M | $274.0M |
| Q4 25 | -14.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.0% | 0.2% | ||
| Q1 25 | -3.6% | 2.1% | ||
| Q4 24 | -25.6% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 12.5% | -3.8% | ||
| Q1 24 | 7.3% | 5.9% |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.1% | 1.9% | ||
| Q3 24 | 0.1% | 1.9% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.1% | 3.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.04× | -0.28× | ||
| Q1 24 | — | 1.12× |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
